Abstract: Implants which are capable of sustained release of a cell proliferation modulating agent, together with methods for their preparation and use, are provided. The proliferation modulating agent is associated either covalently or non-covalently with the material from which the implant is prepared, generally a biologically inert polymer which is physiologically compatible. The implants are implanted in the tissue, and the drug is released such that the drug is substantially retained within the implant region. The device can be used to inhibit cellular proliferation around the implant. The device can be provided as a sterile kit, preferably in a form suitable for immediate use.
Abstract: Intraocular devices together with methods for their preparation and use are provided, which are capable of sustained release of an antiproliferative agent, particularly an immunotoxin comprising a cytotoxic moiety. The intraocular devices are implanted in the eye where the immunotoxin is released from the intraocular device. The device may be used to inhibit proliferation of remnant lens epithelial cells, particularly after extracapsular cataract extractinon. The components of the device can be provided as kits, but preferably are provided in a form suitable for use with an IOL or coated onto an IOL.
Type:
Grant
Filed:
May 3, 1996
Date of Patent:
March 2, 1999
Assignee:
Houston Biotechnology Incorporated
Inventors:
Peter J. Kelleher, Dominic M. K. Lam, Maureen P. Tarsio
Abstract: Intraocular devices which are capable of sustained release of a cell proliferation modulating agent, together with methods for their preparation and use, are provided. The intraocular devices are implanted in the tissue, and the drug is released from the intraocular device such that the drug is substantially retained within the implant region. The device may be used to inhibit cellular proliferation around the implant. The device can be provided as a kit, preferably in a form suitable for use.
Abstract: Novel neurotrophic factor compositions are provided, obtained from lung tissue. The factors are found to be active on parasympathetic ganglion neurons enhancing acetylcholine activity. The compositions find use in the treatment of a number of eye disorders.
Type:
Grant
Filed:
January 21, 1994
Date of Patent:
August 15, 1995
Assignee:
Houston Biotechnology Incorporated
Inventors:
Thomas L. Wallace, David E. Potter, Craig E. Crosson
Abstract: Novel neutrotrophic factor compositions are provided, obtained from lung tissue. The factors are found to be active on parasympathetic ganglion neutrons enhancing acetylcholine activity. The compositions find use in the treatment of a number of eye disorders.
Type:
Grant
Filed:
October 31, 1988
Date of Patent:
November 24, 1992
Assignee:
Houston Biotechnology Incorporated
Inventors:
Thomas L. Wallace, David E. Potter, Craig E. Crosson
Abstract: Phosphatides are shown to have antiviral activity, where the phosphatides are characterized by having a polyunsaturated fatty acid at the sn2 position. By contacting cells susceptible to or infected with a virus, particularly a retrovirus, the proliferation of the virus is substantially inhibited.
Abstract: Neurologic dysfunction resulting from stroke is diminished by administering to a patient an effective amount of a tetra-substituted pyrazine over a relatively continuous regimen. Conveniently, an initial bolus is administered to bring the level of the drug up to a pre-determined blood level, followed by continuous infusion employing a pump or by continuous intravenous infusion.